Cardiff Oncology Inc. Registered Shares DL -,0001

Sector and Industry

Healthcare, Healthcare Equipment

Performance (1Y)

80.22%

Market Cap

-

P/E Ratio

0.00

Dividend Yield

0.00 %

Earnings per Share

-0.61 €

Peer Group

Company NameMarket CapRevenue Last Reported YearP/E RatioProfit Growth 1YLast PricePrevious Trading Day Change
Abbott Laboratories185.26 Bil.39.29 Bil.33.69
-53.32 %
0.00
-
Intuitive Surgical Inc171.24 Bil.8.92 Bil.71.93
+17.90 %
0.00
-
Boston Scientific Corp120.40 Bil.17.79 Bil.49.17
+49.88 %
0.00
-
Stryker Corp.114.47 Bil.22.26 Bil.41.85
+3.99 %
0.00
-
Medtronic PLC90.93 Bil.31.27 Bil.22.35
-4.61 %
0.00
-
Siemens Healthineers AG51.40 Bil.23.38 Bil.24.04
+10.40 %
0.00
-
Hoya Corp48.59 Bil.5.43 Bil.35.69
+17.33 %
0.00
-
Becton Dickinson and Co.45.46 Bil.19.79 Bil.32.18
-3.33 %
0.00
-
Edwards Lifesciences Corp42.15 Bil.5.38 Bil.47.11
-27.44 %
0.00
-
Alcon AG33.20 Bil.9.24 Bil.38.41
-7.56 %
0.00
-

Facts & figures

Price data

TRADE PLATFORMBörse Stuttgart (XSTU)
LAST PRICE0.7315 G0 Units
PRICE DETERMINATION TIME07/21/2026 / 11:18:40 AM
DAILY VOLUME (UNITS)0
DAILY HIGH / LOW0.73150.7275
PREV. DAY'S PRICE0.733 (07/20)
CHANGE DAY BEFORE
-0.00
-0.20 %
52 WEEK HIGH / LOW3.785 (07/24)0.7205 (07/20)

Key Figures (in EUR)

2023202420252026e2027e
EARNINGS PER SHARE
-0.86-0.88-0.61-0.65-0.75
DIVIDENDS PER SHARE
0.000.000.00--
DIVIDEND YIELD IN %
0.00 %0.00 %0.00 %--
DIVIDEND GROWTH IN %
-----
PRICE - EARNINGS RATIO
-----
PRICE - BOOK RATIO
0.953.484.23--
PRICE - SALES RATIO
135.50302.78316.73--
PRICE - CASH FLOW RATIO
-----
Further Key Figures

Master Data

WKN
A2P4GU
ISIN
US14147L1089
SYMBOL
XE7C
EXCHANGE SEGMENT
Freiverkehr
TYPE OF FINANCIAL INSTRUMENT
Equity
DENOMINATION
CARDIFF ONCOLOG. DL-,0001
INDEX MEMBERSHIP
-
TRADING SEGMENT
-
TRADING HOURS
07:30:00 AM - 10:00:00 PM
TRADING CURRENCY
Euro
NOMINAL CURRENCY
-
SETTLEMENT CURRENCY
Euro
SECTOR AND INDUSTRYHealthcare, Healthcare Equipment
NUMBER OF SHARES
-
MARKET CAPITALISATION
-

Performance overview

1W1M3M6M1Y3Y5YYTD
PERFORMANCE
-38.04 %
-30.85 %
-51.42 %
-69.07 %
-80.22 %
-44.72 %
-84.73 %
-70.38 %
HIGH1.211.241.702.573.795.507.002.80
LOW0.720.720.720.720.720.720.720.72

Dividende

pro Aktie
CARDIFF ONCOLOG. DL-,0001 does not deliver dividend information

Company profile

Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. The firm is focused on developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics. Its clinical programs include KRAS-Mutated Metastatic Colorectal Cancer (mCRC), Resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC) and relapsed or refractory Acute Myeloid Leukemia (AML). The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan in 1999 and is headquartered in San Diego, CA.

Shareholder Structure (Top 10)

AnteilName
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available

Analyst Rating

Ø-Target Price DistanceNot Available
Current Price
Not Available
Ø-Target Price
Not Available
Average ResultNot Available
Buy0
Overweight0
Hold0
Underweight 0
Sell0

Company Events

No company events available.